恒瑞医药：子公司HRS-5346片纳入突破性治疗品种名单

Core Viewpoint - Heng Rui Medicine announced that its subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., has had its HRS-5346 tablets included in the list of breakthrough therapies by the National Medical Products Administration's Drug Evaluation Center. HRS-5346 is an oral small molecule inhibitor targeting elevated lipoprotein (a) levels, with no similar products approved for market domestically or internationally [1] Group 1 - HRS-5346 is designed to treat elevated lipoprotein (a) levels [1] - The inclusion in the breakthrough therapy list indicates potential expedited development and review processes [1] - There are currently no comparable products approved for sale in the market, highlighting a unique market opportunity [1]